{"id":"W2041310270","doi":"10.1517/14656566.2012.689130","title":"Sunitinib malate for the treatment of renal cell carcinoma","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Sunitinib; Sunitinib malate; Medicine; Renal cell carcinoma; Tolerability; Tyrosine-kinase inhibitor; Vascular endothelial growth factor; Pazopanib; Oncology; Clinical trial; Dosing; Internal medicine; Pharmacology; Adverse effect; Cancer; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003260778,0.0001905012,0.0004461776,0.0004040888,0.0001917406,0.0003351089,0.0002550436,0.0005132572,0.007637977],"category_scores_gemma":[0.0005543975,0.00004829758,0.0003954064,0.0002430627,0.0001543107,0.0002963502,0.0002406264,0.0009307376,0.002592513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000433391,"about_ca_system_score_gemma":0.0003527354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003986867,"about_ca_topic_score_gemma":0.001289094,"domain_scores_codex":[0.9998325,0.0000438162,0.00001952586,0.00002594811,0.00005814288,0.00001999474],"domain_scores_gemma":[0.9998436,0.00003811153,0.00003880026,0.000005588647,0.00004768974,0.00002617637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009016437,0.00008259965,0.0009618418,0.00418226,0.0001804202,0.001237705,0.00006154763,0.0003217434,0.007606016,0.003204997,0.1163787,0.8648804],"study_design_scores_gemma":[0.0004597264,0.0007982019,0.003718757,0.001074132,0.0001998501,0.00748531,0.00004009195,0.0004172389,0.004980962,0.002270462,0.9785314,0.00002387597],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01350947,0.9122854,0.002249315,0.02363568,0.005184792,0.0001098518,0.0006368727,0.0002401989,0.04214843],"genre_scores_gemma":[0.2760404,0.6326969,0.003957581,0.0218868,0.01191994,0.0001692474,0.00197974,0.00009176118,0.05125753],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007637977,"threshold_uncertainty_score":0.02555156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.192132551629056,"score_gpt":0.4298720621045542,"score_spread":0.2377395104754982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}